TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo shrinks aggressive breast tumors before surgery
Disease control CompletedThis study tested whether adding two extra drugs (carboplatin and/or bevacizumab) to standard chemotherapy before surgery could improve outcomes for people with a fast-growing type of breast cancer called triple-negative. About 450 participants received weekly paclitaxel with or …
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:09 UTC
-
New drug cocktail shrinks tough breast tumors before surgery
Disease control CompletedThis study tested a combination of three drugs (panitumumab, carboplatin, and paclitaxel) given before surgery to women with triple-negative breast cancer whose tumors did not respond to standard chemotherapy. The goal was to shrink tumors and reduce the amount of breast tissue t…
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:04 UTC
-
New drug combo shows promise for tough breast cancer
Disease control CompletedThis study tested a treatment combining enzalutamide (blocks male hormones) and paclitaxel (chemotherapy) given before surgery to women with a specific type of triple-negative breast cancer that has androgen receptors. The goal was to shrink tumors and reduce the amount of breast…
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:04 UTC
-
New drug combo shows promise in shrinking aggressive breast tumors before surgery
Disease control CompletedThis study tested giving a chemotherapy drug (nab-paclitaxel) and an immunotherapy drug (atezolizumab) before surgery to women with triple-negative breast cancer. The goal was to shrink tumors and reduce the amount of breast tissue that needs to be removed. The trial involved 37 …
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tested a new drug (AZD8186) combined with chemotherapy (docetaxel) in 23 people with advanced solid tumors that have certain gene mutations (PTEN or PIK3CB). The main goals were to find the best dose and check for side effects. The study was completed, but …
Matched conditions: TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:08 UTC